Central obesity, type 2 diabetes and insulin: Exploring a pathway full of thorns

Archives of Medical Science

Volumn 11, Issue 3, 2015, Pages 463-482

  Papaetis, Georgios S ^a,b   Papakyriakou, Panagiotis ^c   Panagiotou, Themistoklis N ^b  

^a Diabetes Clinic   (Cyprus)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Paphos General Hospital   (Cyprus)

Author keywords

Adipokines; Cardiovascular disease; Central obesity; Insulin resistance; Non esterified fatty acids; Type 2 diabetes

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPOCYTOKINE; ADIPONECTIN; APELIN; CHEMERIN; ENDOTHELIN 1; FATTY ACID; INSULIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; RETINOL BINDING PROTEIN 4; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN;

ABDOMINAL FAT; ADIPOSE TISSUE; CELL CULTURE; CYTOKINE PRODUCTION; DIABETIC PATIENT; DISEASE ASSOCIATION; FATTY ACID OXIDATION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER; MACROPHAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT REDUCTION;

EID: 84932132647     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.52350     Document Type: Review

References (233)

1. Meigs JB. Epidemiology of type 2 diabetes and cardiovascular disease: translation from population to prevention: the Kelly West award lecture 2009. Diabetes Care 2010; 33: 1865-71.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. Khunti K, Stone MA, Bankart J, et al. Physical activity and sedentary behaviours of South Asian and white European children in inner city secondary schools in the UK. Fam Pract 2007; 24: 237-44.
4. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-9.
5. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997; 146: 214-222.
6. Fagot-Campagna A, Narayan K. Type 2 diabetes in children. BMJ 2001; 322: 377-87.
7. Urbanavičius V, Abalikšta T, Brimas G, Abraitienė A, Gogelienë L, Strupas K. Comparison of changes in blood glucose, insulin resistance indices, and adipokine levels in diabetic and non-diabetic subjects with morbid obesity after laparoscopic adjustable gastric banding. Medicina (Kaunas) 2013; 49: 9-14.
8. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10.
9. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25: 1177-84.
10. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson BW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30: 1219-25.
11. Bavenholm P, Proudler A, Tornvall P, et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995; 92: 1422-9.
12. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 2012; 12: 148-58.
13. Schaper NC, Nabuurs-Franssen MH, Huijberts MS. Peripheral vascular disease and type 2 diabetes mellitus. Diabetes Metab Res Rev 2000; 16 (Suppl 1): S11-5.
14. Kasuga MF, Karlsson A, Kahn CR. Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 1982; 215: 185-6.
15. Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991; 352: 73-7.
16. Skolnik EY, Lee CH, Batzer A, et al. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 1993; 12: 1929-36.
17. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 2002; 3: 267-77.
18. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000; 105: 311-20.
19. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by Wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-8.
20. Carel K, Kummer JL, Schubert C, Leitner W, Heidenreich KA, Draznin B. Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes. J Biol Chem 1996; 271: 30625-30.
21. Currie RA, Walker KS, Gray A, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999; 337: 575-83.
22. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346: 561-76.
23. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001; 21: 5050-62.
24. McGettrick AJ, Feener EP, Kahn CR. Human insulin receptor substrate-1 (IRS-1) polymorphism G972R causes IRS-1 to associate with the insulin receptor and inhibit receptor autophosphorylation. J Biol Chem 2005; 280: 6441-6.
25. van de Weijer T, Sparks LM, Phielix E, et al. Relationships between mitochondrial function and metabolic flexibility in type 2 diabetes mellitus. PLoS One 2013; 8: e51648.
26. Bajaj M, Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes 2002; 51 (Suppl 3): S405.
27. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci 2013; 9: 191-200.
28. Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med 2009; 360: 1518-25.
29. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) family study. Diabetes 2003; 52: 2490-6.
30. Zierath JR, Livingston JN, Thorne A, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia 1998; 41: 1343-54.
31. Papaetis GS, Orphanidou D, Panagiotou TN. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit. Curr Drug Targets 2011; 12: 1498-512.
32. Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005; 115: 3587-93.
33. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
34. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-4.
35. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 1997; 272: 971-6.
36. Guo L, Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther 2006; 111: 145-73.
37. Steinberg GR, Michell BJ, van Denderen BJ, et al. Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 2006; 4: 465-74.
38. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-6.
39. de Meijer VE, Le HD, Meisel JA, Sharma AK, Popov Y, Puder M. Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One 2011; 6: e25587.
40. Hivert MF, Sullivan LM, Shrader P, et al. The association of tumor necrosis factor alpha receptor 2 and tumor necrosis factor alpha with insulin resistance and the influence of adipose tissue biomarkers in humans. Metabolism 2010; 59: 540-6.
41. Ursini F, Naty S, Grembiale RD. Infliximab and insulin resistance. Autoimmun Rev 2010; 9: 536-9.
42. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.
43. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006; 166: 902-8.
44. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-9.
45. Dominguez H, Storgaard H, Rask-Madsen C, et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-25.
46. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-50.
47. Hrnciar J, Avdicova M, Gabor D, et al. Prevalence of metabolic syndrome, insulin resistance, and microvascular angina pectoris in 500 consecutive patients referred to coronarography. Endocr Regul 2013; 47: 33-8.
48. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-7.
49. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-9.
50. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor alpha, overexpressed in human fat cells from insulin resistant subjects. J Biol Chem 2003; 278: 45777-84.
51. Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 2006; 20: 3364-75.
52. Pedersen BK, Akerstrom TC, Nielsen AR, Fischer CP. Role of myokines in exercise and metabolism. J Appl Physiol 2007; 103: 1093-8.
53. Wallenius K, Wallenius V, Sunter D, Dickson SL, Jansson JO. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 2002; 293: 560-5.
54. Bastard JP, Lagathu C, Caron M, Capeau J. Point-counterpoint: interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 2007; 102: 821-2.
55. Jager J, Gremeaux T, Cormont M, Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148: 241-51.
56. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 314-21.
57. Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol 2007; 27: 98-114.
58. Netea MG, Joosten LA, Lewis E, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med 2006; 12: 650-6.
59. Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 2005; 117: 152-60.
60. Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 2001; 175: 81-92.
61. Kobashi C, Asamizu S, Ishiki M, et al. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm (Lond) 2009; 6: 25.
62. Samaras K, Botelho NK, Chisholm DJ, Lord RV. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 2010; 18: 884-9.
63. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006; 7: 761-71.
64. Minokoshi Y, Kim YB, Peroni OD, Fryer LGD, Müller C, Carling D. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415: 339-43.
65. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999; 48: 1487-92.
66. Muzzin P, Eisensmith RC, Copeland KC, Woo SL. Correction of obesity and diabetes in genetically obese mice by leptin gene therapy. Proc Natl Acad Sci USA 1996; 93: 14804-8.
67. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J 2002; 16: 1163-76.
68. Askari H, Tykodi G, Liu J, Dagogo-Jack S. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. J Clin Endocrinol Metab 2010; 95: 3836-43.
69. Rahmouni K, Morgan DA, Morgan GM, Mark AL, Haynes WG. Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005; 54: 2012-8.
70. Frühbeck G, Salvador J. Relation between leptin and the regulation of glucose metabolism. Diabetologia 2000; 43: 3-12.
71. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52: 1201-10.
72. Hennige AM, Stefan N, Kapp K, et al. Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1. FASEB J 2006; 20: 1206-8.
73. Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab 2006; 17: 365-71.
74. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-6.
75. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359: 46-7.
76. Junkin KA, Dyck DJ, Mullen KL, Chabowski A, Thrush AB. Resistin acutely impairs insulin-stimulated glucose transport in rodent muscle in the presence, but not absence, of palmitate. Am J Physiol Regul Integr Comp Physiol 2009; 296: R944-5.
77. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-8.
78. Qi Y, Nie Z, Lee YS, et al. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 2006; 55: 3083-90.
79. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009; 10: 96-107.
80. Tzatsos A, Kandror KV. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 2006; 26: 63-76.
81. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174: 5789-95.
82. Graveleau C, Zaha VG, Mohajer A, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005; 280: 31679-85.
83. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002; 10: 1-5.
84. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003; 88: 4848-56.
85. Utzschneider KM, Carr DB, Tong J, et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48: 2330-3.
86. Park HK, Qatanani M, Briggs ER, Ahima RS, Lazar MA. Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice. Diabetes 2011; 60: 775-83.
87. Janke J, Engeli S, Boschmann M, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006; 55: 2805-10.
88. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-62.
89. Graham TE, Yang Q, Bluher M, et al. Retinol binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-63.
90. Stefan N, Hennige AM, Staiger H, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat, but not with total-, subcutaneous-, visceral-, or intramyocellular fat in humans. Diabetes Care 2007; 30: 1173-8.
91. Haider DG, Schindler K, Prager G, et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 2007; 92: 1168-71.
92. Lim S, Choi SH, Jeong IK, et al. Insulin-sensitizing effects of exercise on adiponectin and retinol binding protein-4 concentrations in young and middle-aged women. J Clin Endocrinol Metab 2008; 93: 2263-8.
93. Refai E, Dekki N, Yang SN, et al. Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling. Proc Natl Acad Sci USA 2005; 102: 17020-5.
94. Henze A, Frey SK, Raila J, et al. Evidence that kidney function but not type 2 diabetes determines retinolbinding protein 4 serum levels. Diabetes 2008; 57: 3323-6.
95. Ribel-Madsen R, Friedrichsen M, Vaag A, Poulsen P. Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes 2009; 58: 54-60.
96. Broch M, Vendrell J, Ricart W, Richart C, Fernández-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007; 30: 1802-6.
97. von Eynatten M, Lepper PM, Liu D, et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 2007; 50: 1930-7.
98. Yao-Borengasser A, Varma V, Bodles AM, et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007; 92: 2590-7.
99. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005; 90: 2282-9.
100. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 7265-70.
101. Kouyama K, Miyake K, Zenibayashi M, et al. Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J Med Sci 2008; 53: 345-54.
102. Inouye KE, Shi H, Howard JK, et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007; 56: 2242-50.
103. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82.
104. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562-8.
105. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-9.
106. Lopez-Alemany R, Redondo JM, Nagamine Y, Munoz-Canoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur J Biochem 2003; 270: 814-21.
107. Lijnen HR, Alessi MC, Van Hoef B, Collen D, Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005; 3: 1174-9.
108. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131-7.
109. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first myocardial infarction in both men and women. Circulation 1998; 98: 2241-7.
110. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004; 97: 673-8.
111. Yang RZ, Lee MJ, Hu H, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3: e287.
112. Sjöholm K, Palming J, Olofsson LE, et al. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 2005; 90: 2233-9.
113. Ye XY, Xue YM, Sha JP, Li CZ, Zhen ZJ. Serum amyloid A attenuates cellular insulin sensitivity by increasing JNK activity in 3T3-L1 adipocytes. J Endocrinol Invest 2009; 32: 568-75.
114. Badolato R, Wang JM, Murphy WJ, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180: 203-9.
115. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol 1998; 48: 410-418.
116. Jylhava J, Haarala A, Eklund C, et al. Serum amyloid A is independently associated with metabolic risk factors but not with early atherosclerosis: the Cardiovascular Risk in Young Finns Study. J Intern Med 2009; 266: 286-95.
117. Scheja L, Heese B, Zitzer H, et al. Acute-phase serum amyloid A as a marker of insulin resistance in mice. Exp Diabetes Res 2008; 2008: 230837.
118. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-40.
119. Shih KC, Kwok CF, Ho LT. Combined use of insulin and endothelin-1 causes decrease of protein expression of beta-subunit of insulin receptor, insulin receptor substrate-1, and insulin-stimulated glucose uptake in rat adipocytes. J Cell Biochem 2000; 78: 231-40.
120. Jiang ZY, Zhou QL, Chatterjee A, et al. Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999; 48: 1120-30.
121. Ishibashi KI, Imamura T, Sharma PM, Huang J, Ugi S, Olefsky JM. Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes. J Clin Invest 2001; 107: 1193-202.
122. Hauner H, Petruschke T, Gries FA. Endothelin-1 inhibits the adipose differentiation of cultured human adipocyte precursor cells. Metabolism 1994; 43: 227-32.
123. Mangiafico RA, Malatino LS, Santonocito M, Spada RS. Plasma endothelin-1 concentrations in non-insulin-dependent diabetes mellitus and nondiabetic patients with chronic arterial obstructive disease of the lower limbs. Int Angiol 1998; 17: 97-102.
124. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856-62.
125. Sarafidis PA, Bakris GL. Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007; 92: 379-85.
126. Piatti PM, Monti LD, Conti M, et al. Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 1996; 45: 316-21.
127. van Harmelen V, Eriksson A, Aström G, Wåhlén K, Näslund E, Karpe F. Vascular peptide endothelin-1 links fat accumulation with alterations of visceral adipocyte lipolysis. Diabetes 2008; 57: 378-86.
128. Mathai ML, Chen N, Cornall L, Weisinger RS. The role of angiotensin in obesity and metabolic disease. Endocr Metab Immune Disord Drug Targets 2011; 11: 198-205.
129. Giacchetti G, Faloia E, Mariniello B, et al. Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens 2002; 15: 381-8.
130. Massiéra F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001; 15: 2727-9.
131. Tomono Y, Iwai M, Inaba S, Mogi M, Horiuchi M. Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models. Am J Hypertens 2008; 21: 206-12.
132. Saint-Marc P, Kozak LP, Ailhaud G, Darimont C, Negrel R. Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation. Endocrinology 2001; 142: 487-92.
133. Ferder L, Inserra F, Martínez-Maldonado M. Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress. Curr Hypertens Rep 2006; 8: 191-8.
134. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100: 2158-69.
135. Iwai M, Chen R, Imura Y, Horiuchi M. TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation. Am J Hypertens 2007; 20: 579-86.
136. Golovchenko I, Goalstone ML, Watson P, Brownlee M, Draznin B. Hyperinsulnemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells. Circ Res 2000; 87: 746-62.
137. Perkins JM, Davis SN. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes 2008; 15: 147-52.
138. Kalupahana NS, Massiera F, Quignard-Boulange A, et al. Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity (Silver Spring) 2012; 20: 48-56.
139. Napoli C, Paolisso G, Casamassimi A, et al. Effects of nitric oxide on cell proliferation: novel insights. J Am Coll Cardiol 2013; 62: 89-95.
140. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol 2008; 49: 134-40.
141. Ryden M, Elizalde M, van Harmelen V, et al. Increased expression of eNOS protein in omental versus subcutaneous adipose tissue in obese human subjects. Int J Obes Relat Metab Disord 2001; 25: 811-5.
142. Xue HM, Yu CM, Underwood MJ, Huang JH, Yang Q. AVE3085 protects coronary endothelium from the impairment of asymmetric dimethylarginine by activation and recoupling of eNOS. Cardiovasc Drugs Ther 2012; 26: 383-92.
143. Mills CD. M1 and M2 macrophages: oracles of health and disease. Crit Rev Immunol 2012; 32: 463-88.
144. Charbonneau A, Marette A. Inducible nitric oxide synthase induction underlies lipid-induced hepatic insulin resistance in mice: potential role of tyrosine nitration of insulin signaling proteins. Diabetes 2010; 59: 861-71.
145. Tsuchiya K, Sakai H, Suzuki N, et al. Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice. Endocrinology 2007; 148: 4548-56.
146. Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 2008; 117: 1594-602.
147. Kleemann R, Bucala R. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm 2010; 2010: 610479.
148. Hristova M, Aloe L. Metabolic syndrome-neurotrophic hypothesis. Med Hypotheses 2006; 66: 545-9.
149. Bullo M, Peeraully MR, Trayhurn P, Folch J, Salas-SalvadóJ. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur J Endocrinol 2007: 157: 303-10.
150. Murray I, Kôhl J, Cianflone K. Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity. Biochem J 1999; 342: 41-8.
151. MacLaren RE, Cui W, Lu HL, Simard S, Cianflone K. Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects. BMC Med Genomics 2010; 3: 3.
152. Xita N, Tsatsoulis A. Adiponectin in diabetes mellitus. Curr Med Chem 2012; 19: 5451-8.
153. Athyros VG, Tziomalos K, Karagiannis A, Anagnosits P, Mikhailidis GP. Should adipokines be considered in the choice of the treatment of obesity-related health problems? Curr Drug Targets 2010; 11: 122-35.
154. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
155. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-81.
156. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008; 409: 623-33.
157. Yang WS, Lee WJ, Funahashi T, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-9.
158. Ajuwon KM, Spurlock ME. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005; 288: R12200-25.
159. Wang C, Mao X, Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 2007; 282: 7991-6.
160. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-9.
161. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005; 46: 1369-79.
162. Okamoto M, Ohara-Imaizumi M, Kubota N, et al. Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 2008; 51: 827-35.
163. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9.
164. Daimon M, Oizumi T, Saitoh T, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 2003; 26: 2015-20.
165. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003; 26: 3226-9.
166. Snijder MB, Heine RJ, Seidell JC, et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care 2006; 29: 2498-503.
167. Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the diabetes prevention program. Diabetes 2008; 57: 980-6.
168. Mente A, Razak F, Blankenberg S, et al. Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. Diabetes Care 2010; 33: 1629-34.
169. de Luis DA, Aller R, Gonzalez Sagrado M, Conde R, Izaola O, de la Fuente B. Serum visfatin levels and metabolic syndrome criteria in obese female subjects. Diabetes Metab Res Rev 2013; 29: 576-81.
170. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30.
171. Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-75.
172. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-9.
173. Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-81.
174. Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 11: 544-8.
175. Brema I, Hatunic M, Finucane F, et al. Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus. Diabetes Obes Metab 2008; 10: 600-2.
176. Eyileten T, Sonmez A, Saglam M, et al. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010; 15: 225-9.
177. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010; 118: 75-80.
178. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-6.
179. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91: 3165-70.
180. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf) 2007; 67: 796-800.
181. Ko BJ, Lee M, Park HS, et al. Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children. Endocr J 2013; 60: 609-16.
182. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102: 10610-5.
183. Wada J. Vaspin: a novel serpin with insulin-sensitising effects. Expert Opin Investig Drugs 2008; 17: 327-33.
184. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372-7.
185. Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339: 430-6.
186. Tan BK, Heutling D, Chen J, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008; 57: 1501-7.
187. Yang R, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290: E1253-61.
188. Lee JK, Schnee J, Pang M, et al. Human homologs of the Xenopus oocyte cortical granule lectin XL35. Glycobiology 2001; 11: 65-73.
189. Fain JN, Sacks HS, Buehrer B, et al. Identification of omentin-1 mRNA in human epicardial adipose tissue: comparison to omentin-1 in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 2008; 32: 810-5.
190. de Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007; 56: 1655-61.
191. Moreno-Navarrete JM, Catalán V, Ortega F, et al. Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 2010; 7: 27.
192. Wurm S, Neumeier M, Weigert J, Schäffler A, Buechler C. Plasma levels of leptin, omentin, collagenous repeat-containing sequence of 26-kDa protein (CORS-26) and adiponectin before and after oral glucose uptake in slim adults. Cardiovasc Diabetol 2007; 6: 7-13.
193. Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008; 8: 437-45.
194. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116: 289-92.
195. Dray C, Debard C, Jager J, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab 2010; 298: E1161-9.
196. Wittamer V, Franssen JD, Vulcano M, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977-85.
197. Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687-94.
198. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin: a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282: 28175-88.
199. Takahashia M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Letters 2008; 582: 573-8.
200. Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009; 58: 2731-40.
201. Santomauro ATMG, Boden G, Silva M, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-41.
202. Il'yasova D, Wang F, D'Agostino RB Jr, Hanley A, Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. Diabetologia 2010; 53: 866-74.
203. Abdul-Ghani MA, Ubhayasekera SJ, Staaf J, Forslund A, Bergsten P, Bergquist J. Free fatty acid determination in plasma by GC-MS after conversion to Weinreb amides. Anal Bioanal Chem 2013; 405: 1929-35.
204. Hansen D, Dendale P, Beelen M, et al. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur J Appl Physiol 2010; 109: 397-404.
205. Kashyap S, Belfort R, Berria R, et al. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab 2004; 287: E537-46.
206. Gao Z, Zhang X, Zuberi A, et al. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol Endocrinol 2004; 18: 2024-34.
207. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-92.
208. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45: 42-72.
209. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 1997; 100: 1230-9.
210. Cerosismo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diab Metab Res Rev 2006; 22: 423-36.
211. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003; 100: 8466-71.
212. Abdul-Ghani MA, DeFronzo RA. Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus. Curr Diab Rep 2008; 8: 173-8.
213. Armoni M, Harel C, Bar-Yoseph F, Milo S, Karnieli E. Free fatty acids repress the Glut4 gene expression in cardiac muscle via novel response elements. J Biol Chem 2005; 280: 34786-95.
214. Ismail NA, Ragab S, El Dayem SM, et al. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci 2012; 8: 826-33.
215. Graham TE, Wason CJ, Blüher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 2007; 50: 814-23.
216. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011; 60: 63-70.
217. Stępień M, Wlazeł RN, Paradowski M, et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study. Arch Med Sci 2012; 8: 431-6.
218. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabetes Care 2009; 32 (Suppl 1): S13-61.
219. Ertek S, Cicero A. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Arch Med Sci 2012; 8: 794-804.
220. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-9.
221. Golay A. Metformin and body weight. Int J Obes 2008; 32: 61-72.
222. Krakoff J, Clark JM, Crandall JP, et al. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010; 18: 1762-7.
223. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009; 76 (Suppl 5): S28-38.
224. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010; 10: 20.
225. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32: 515-31.
226. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012; 5: 313-27.
227. Gill RS, Sharma AM, Al-Adra DP, Birch DW, Karmali S. The impact of bariatric surgery in patients with type-2 diabetes mellitus. Curr Diabetes Rev 2011; 7: 185-9.
228. Lautz D, Halperin F, Goebel-Fabbri A, Goldfine AB. The great debate: medicine or surgery: what is best for the patient with type 2 diabetes? Diabetes Care 2011; 34: 763-70.
229. Iaconelli A, Panunzi S, De Gaetano A, et al. Effects of bilio-pancreatic diversion on diabetes complications: a 10-year follow-up. Diabetes Care 2011; 34: 561-7.
230. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65.
231. Dardeno TA, Chou SH, Moon HS, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in human physiology and therapeutics. Front Neuroendocrinol 2010; 31: 377-93.
232. DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 2010; 123 (3 Suppl): S38-48.
233. Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO. Managing type 2 diabetes: going beyond glycemic control. J Manag Care Pharm 2008; 14 (5 Suppl B): s2-19.